Lobbying Filing Details

Total Spending

$60,000

Activities

4

Lobbyists

6

Gov't Entities

12

Filing Information
Filing UUID:
84bf7c6c-e6ff-46c2-a624-5908d37a54ba
Type:
Q2 - 2nd Quarter - Report
Period:
2026 - 2nd Quarter (Apr 1 - June 30)
Date Posted:
July 17, 2026 at 6:14 PM
Income:
$60,000
Expenses:
$0
Document URL:
View Submission
Quick Info
  • Document Type: text/html
  • Posted By: William Minor, Partner
Registrant
DLA PIPER LLP (US)

Law firm.

Washington, District of Columbia
Client
BIOTECHNOLOGY INNOVATION ORGANIZATION

Advocacy organization for the biotechnology industry.

District of Columbia, United States of America
Lobbying Activities (4)
Activity 1
Health Issues

Issues related to PAHPA reauthorization. Rare Pediatric Disease Priority Review Voucher Program reauthorization. Issues related to drug pricing and value generally. Issues related to pharmacy benefit managers and reporting requirements. 340B. Orphan drugs. Supply chain. Vaccine policy. Issues related to FDA, drug development, and clinical trial requirements.

Lobbyists (6)
  • MR. JAMIE ALEXEI GREGORIAN
  • MARGARET MARTIN
  • RACHEL PORTMAN
  • KARINA LYNCH
  • RICHARD BURR
  • VINCENT SARUBBI JR
Government Entities (3)
  • SENATE
  • HOUSE OF REPRESENTATIVES
  • Food & Drug Administration (FDA)
Activity 2
Medical/Disease Research/Clinical Labs

Issues related to PAHPA reauthorization. Rare Pediatric Disease Priority Review Voucher Program reauthorization. Issues related to drug pricing and value generally. Issues related to pharmacy benefit managers and reporting requirements. 340B. Orphan drugs. Supply chain. Vaccine policy. Issues related to FDA, drug development, and clinical trial requirements.

Lobbyists (6)
  • MR. JAMIE ALEXEI GREGORIAN
  • MARGARET MARTIN
  • RACHEL PORTMAN
  • KARINA LYNCH
  • RICHARD BURR
  • VINCENT SARUBBI JR
Government Entities (3)
  • SENATE
  • HOUSE OF REPRESENTATIVES
  • Food & Drug Administration (FDA)
Activity 3
Medicare/Medicaid

Issues related to reimbursement under Medicare Part B and Part D. Medicare and Medicaid payment and coverage issues. IRA implementation.

Lobbyists (6)
  • MR. JAMIE ALEXEI GREGORIAN
  • MARGARET MARTIN
  • RACHEL PORTMAN
  • KARINA LYNCH
  • RICHARD BURR
  • VINCENT SARUBBI JR
Government Entities (3)
  • SENATE
  • HOUSE OF REPRESENTATIVES
  • Food & Drug Administration (FDA)
Activity 4
Pharmacy

340B drug discount program. General issues related to health care. Issues related to FDA drug review, including PDUFA.

Lobbyists (6)
  • MR. JAMIE ALEXEI GREGORIAN
  • MARGARET MARTIN
  • RACHEL PORTMAN
  • KARINA LYNCH
  • RICHARD BURR
  • VINCENT SARUBBI JR
Government Entities (3)
  • SENATE
  • HOUSE OF REPRESENTATIVES
  • Food & Drug Administration (FDA)

Source: LDA.gov, data retrieved November 5, 2026. FilingExplorer is not affiliated with LDA.gov; the Senate Office of Public Records cannot vouch for data or analyses derived from these records after retrieval.